Research advances in blood-based biomarkers for moyamoya disease
10.12025/j.issn.1008-6358.2026.20251648
- VernacularTitle:烟雾病血液生物标志物研究进展
- Author:
Ziyang HE
1
;
Zhi LI
1
;
Zhang SHI
2
;
Zhigang YANG
3
Author Information
1. Shanghai Medical College, Fudan University, Shanghai 200032, China.
2. Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
3. Department of Neurosurgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
- Publication Type:Review
- Keywords:
moyamoya disease;
biomarker;
multiomics;
bioinformatics;
machine learning
- From:
Chinese Journal of Clinical Medicine
2026;33(5):887-892
- CountryChina
- Language:Chinese
-
Abstract:
Moyamoya disease (MMD) is characterized by progressive stenosis or occlusion of the distal internal carotid artery and its major branches, with secondary formation of abnormal collateral vessels at the skull base. Previous studies evaluated peripheral blood molecules to reflect vascular pathology and inflammation of MMD, but their limited specificity and susceptibility to confounding factors restricted clinical utility. With advances in high-throughput omics, blood-based biomarkers with improved specificity have been identified, and bioinformatics and machine learning have facilitated biomarker screening and diagnostic model development. Meanwhile, biomarkers for different clinical scenarios have emerged, promoting a shift from “diagnostic” to “decision-making” and “predictive” biomarkers. This review summarizes recent studies in blood-based biomarkers for MMD, aiming to provide references for future in-depth studies and clinical translation.
